Skip to main content
Interview with the Innovators

Choosing Maintenance Therapy in Ovarian Cancer

Amina Ahmed, MD
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Ali McBride, PharmD, MS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor.

Related Items